LANGHORNE, Pa., March 04, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced that Adam Levy, Chief Executive Officer, is scheduled to present at the iAccess Alpha Best Ideas Spring Virtual Conference taking place March 12th and 13th.
iAccess Alpha Best Ideas Spring Virtual Conference
Presentation Date: March 12, 2024
Presentation Time: 10:30 a.m. ET
Live Webcast Registration: https://www.webcaster4.com/Webcast/Page/3024/50043
To schedule a 1x1 meeting, please contact your iAccess Alpha conference representative or KCSA by emailing This email address is being protected from spambots. You need JavaScript enabled to view it..
About NEXGEL, INC.
NEXGEL is a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. NEXGEL brands include Silverseal, Hexagels, Turfguard, Kenkoderm, and Dermablock. Additionally, NEXGEL has strategic contract manufacturing relationships with leading consumer healthcare companies.
Investor Contacts:
Valter Pinto, Managing Director
KCSA Strategic Communications
212.896.1254
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$2.38 |
Daily Change: | -0.02 -0.63 |
Daily Volume: | 3,074 |
Market Cap: | US$18.170M |
August 12, 2025 August 05, 2025 May 13, 2025 |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load